Core Insights - The animal health sector experienced a slight increase of 0.01% on October 9, with the leading stock being Driveline [1] - The Shanghai Composite Index closed at 3933.97, up 1.32%, while the Shenzhen Component Index closed at 13725.56, up 1.47% [1] Stock Performance - Driveline (920275) closed at 9.57, up 1.38%, with a trading volume of 17,600 and a turnover of 11.63 million [1] - Jinhai Biological (002688) closed at 6.77, up 1.20%, with a trading volume of 183,400 and a turnover of 123 million [1] - Biological Shares (600201) closed at 9.73, up 0.93%, with a trading volume of 470,500 [1] - Huisheng Biological (300871) closed at 20.90, up 0.87%, with a trading volume of 41,600 [1] - Other notable stocks include Plai Ke (603566) at 13.82, up 0.58%, and Haili Biological (603718) at 6.81, up 0.15% [1] Capital Flow - The animal health sector saw a net outflow of 53.09 million from institutional investors, while retail investors had a net inflow of 28.12 million [2] - The total net inflow from speculative funds was 24.97 million [2] Individual Stock Capital Flow - Ruipu Biological (300119) had a net inflow of 7.31 million from institutional investors, while it experienced a net outflow of 9.14 million from retail investors [3] - Plai Ke (603566) saw a net inflow of 2.41 million from institutional investors but a net outflow of 6.28 million from retail investors [3] - Other stocks like *ST Green Kang (002868) and Jinhai Biological (002688) experienced significant net outflows from institutional investors [3]

Core Viewpoint - The animal health sector experienced a rise of 0.98% on September 30, with *ST Lvkang leading the gains, while the overall market indices also showed positive movement [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 3882.78, up 0.52% [1]. - The Shenzhen Component Index closed at 13526.51, up 0.35% [1]. - The animal health sector's individual stock performance is detailed in a table, highlighting various stocks' closing prices and percentage changes [1]. Group 2: Stock Performance - *ST Lvkang (002868) closed at 28.01, with a gain of 3.51% and a trading volume of 16,700 shares, amounting to approximately 46.61 million yuan [1]. - Other notable stocks include: - Biological Shares (600201) at 9.64, up 1.69% with a trading volume of 412,400 shares [1]. - Jinhe Biological (002688) at 6.69, up 1.67% with a trading volume of 150,600 shares [1]. - KQ Bio (688526) at 17.72, up 1.37% with a trading volume of 32,700 shares [1]. Group 3: Capital Flow - The animal health sector saw a net inflow of 3.40 million yuan from institutional investors, while retail investors experienced a net outflow of 28.01 million yuan [2][3]. - The detailed capital flow for individual stocks indicates varying levels of net inflow and outflow among different companies [3]. - For instance, Biological Shares (600201) had a net inflow of approximately 19.60 million yuan from institutional investors, while *ST Lvkang (002868) faced a net outflow of about 6.49 million yuan [3].

Core Viewpoint - The company has received a new veterinary drug registration certificate for a combined vaccine targeting three major viral diseases in cats, which is expected to enhance its product offerings and market competitiveness in the pet healthcare sector [1][5]. Group 1: New Veterinary Drug Information - The new veterinary drug is a combined inactivated vaccine for feline panleukopenia, feline calicivirus, and feline herpesvirus type 1, with specific viral strains included [1]. - The vaccine is classified as a Class III veterinary drug and contains specific viral loads per dose, ensuring effective immunization [1]. - The vaccine is intended for subcutaneous injection in healthy cats aged 8 weeks and older, with a primary dose followed by annual boosters [2]. Group 2: Research and Development Background - The development of the new vaccine involved a total investment of 8.03 million yuan in research and development [3]. - The targeted viruses are among the most prevalent and harmful to domestic and wild feline populations, highlighting the vaccine's importance in disease prevention [3]. - The vaccine boasts several advantages, including high immunogenicity, prolonged immunity duration of at least 12 months, reduced side effects, and stable production quality [3]. Group 3: Market Context - Currently, there is one imported vaccine and one domestic vaccine that have received registration and are available in the market, along with ten domestic vaccines that have received temporary approval [3]. - The successful development of this new vaccine reflects the company's commitment to innovation and strengthens its position in the pet vaccine market [5]. Group 4: Regulatory Requirements - Before the vaccine can be marketed, it must obtain a veterinary product approval number from the Ministry of Agriculture and Rural Affairs [4]. Group 5: Impact on the Company - The acquisition of the new veterinary drug certificate is expected to drive performance growth for the company, enhance its product competitiveness, and support disease prevention in pets [5].

Core Points - The company, Pulaike, announced the approval of a new veterinary drug by the Ministry of Agriculture and Rural Affairs, which includes a trivalent inactivated vaccine for feline panleukopenia, calicivirus disease, and rhinotracheitis [1] Group 1 - The new veterinary drug is a combination vaccine consisting of strains 708, 60, and 64 [1] - The approval was granted following the review process outlined in the Veterinary Drug Management Regulations and the Veterinary Drug Registration Measures [1] - The new veterinary drug registration certificate was officially issued on September 29, 2025, as per the announcement [1]

Group 1 - Yinglian Co., Ltd. expects a net profit increase of 1531.13% to 1672.97% year-on-year for the first three quarters of 2025, with projected revenue of 1.63 billion to 1.65 billion yuan, a growth of 9.49% to 10.83% [1] - Meixin Sheng plans to reduce its shareholding by no more than 1% through centralized bidding and block trading [1] - Huayin Technology signed two sales contracts totaling 402 million yuan, with one contract for special functional materials and another for research project materials [3] Group 2 - Shen Highways reported a total toll revenue of 114 million yuan for August [5] - Dash Smart signed a contract worth 113 million yuan for a smart hospital project [7] - Tianbang Food received an administrative regulatory measure decision from the China Securities Regulatory Commission for failing to disclose information in a timely manner [8] Group 3 - Fashilong plans to invest 250 million yuan to establish a wholly-owned subsidiary focused on AI applications and cloud computing [10] - Junpu Intelligent received a government subsidy of 20 million yuan, accounting for 243.97% of its audited net profit for 2024 [11] - Longyun Co. plans to apply for a bank credit limit of 32 million yuan [12] Group 4 - Yifan Pharmaceutical's subsidiary received acceptance for a drug registration application for a medication used to lower phenylalanine levels in patients [12] - Rundu Co. received a drug registration certificate for a hypertension medication [13] - Huahai Qingke elected a new employee director and appointed a new vice president [17] Group 5 - Wanyi Technology received a government subsidy of 173,000 yuan [19] - Haizheng Pharmaceutical's tacrolimus capsules passed the consistency evaluation for generic drugs [20] - Pulaike's new veterinary vaccine received registration certification [22] Group 6 - Boguang New Materials signed a major sales contract estimated at 4.3 billion to 5 billion yuan for nickel powder products [41] - Electric Soul Network announced plans for shareholders to reduce their holdings by up to 1.63% [42] - Jin Haitong's shareholders plan to reduce their holdings by up to 3% [44]

Core Insights - The animal health sector experienced a slight increase of 0.46% on September 29, with Shenlian Biological leading the gains [1] - The Shanghai Composite Index closed at 3862.53, up 0.9%, while the Shenzhen Component Index closed at 13479.43, up 2.05% [1] Stock Performance - Shenlian Biological (688098) closed at 10.59, up 1.92% with a trading volume of 68,700 shares and a turnover of 72.32 million yuan [1] - Other notable performers included: - Biological Shares (600201) at 9.48, up 1.50% with a turnover of 503 million yuan [1] - Pulaike (603566) at 13.78, up 1.03% with a turnover of 54.30 million yuan [1] - Zhongmu Shares (600195) at 7.12, up 0.85% with a turnover of 49.02 million yuan [1] Capital Flow - The animal health sector saw a net outflow of 7.69 million yuan from institutional investors, while retail investors contributed a net inflow of 8.08 million yuan [2] - The detailed capital flow for key stocks includes: - Shenlian Biological: net outflow of 5.50 million yuan from retail investors [3] - Biological Shares: net outflow of 7.67 million yuan from retail investors [3] - Pulaike: net outflow of 4.08 million yuan from retail investors [3]

Core Viewpoint - The company, Prike (603566.SH), has received approval from the Ministry of Agriculture and Rural Affairs for a new veterinary drug aimed at preventing three feline diseases, marking a significant development in its product offerings [1] Group 1: Product Approval - The new veterinary drug is a trivalent inactivated vaccine for feline panleukopenia, feline calicivirus, and feline infectious respiratory disease [1] - The vaccine was jointly submitted by the company and its wholly-owned subsidiaries, Luoyang Huizhong Biotechnology Co., Ltd. and Luoyang Huizhong Animal Health Co., Ltd. [1] - The new veterinary drug registration certificate was officially issued on September 29, 2025, as per the announcement from the Ministry of Agriculture and Rural Affairs [1] Group 2: Vaccine Efficacy - The vaccine is designed to prevent feline panleukopenia, feline calicivirus disease, and feline infectious respiratory disease [1] - The immune response is expected to develop within 7 days after the second vaccination, with an immunity duration of 12 months [1]

根据《兽药管理条例》和《兽药注册办法》规定，经农业农村部审查，批准 普莱柯生物工程股份有限公司（以下简称"公司"）及全资子公司洛阳惠中生物 技术有限公司（以下简称"惠中生物"）、洛阳惠中动物保健有限公司（以下简 称"惠中动保"）等单位联合申报的"猫泛白细胞减少症、杯状病毒病、鼻气管 炎三联灭活疫苗（708 株+60 株+64 株）"为新兽药，并于 2025 年 9 月 29 日公 示了核发《新兽药注册证书》（中华人民共和国农业农村部公告第 953 号）事项。 详情如下： 一、新兽药的基本信息 新兽药名称：猫泛白细胞减少症、杯状病毒病、鼻气管炎三联灭活疫苗（708 株+60 株+64 株） 证券代码：603566 证券简称：普莱柯 公告编号：2025-039 普莱柯生物工程股份有限公司 关于获得新兽药注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 注册分类：三类 主要成分与含量：每头份疫苗中含灭活的猫泛白细胞减少症病毒 708 株 10 5.7FAID50，含灭活的猫杯状病毒 60 株 10 9.0TCID50， ...

Core Viewpoint - The company, Prike (603566.SH), has received approval from the Ministry of Agriculture and Rural Affairs for a new veterinary drug aimed at preventing three feline diseases, marking a significant advancement in its product offerings [1] Group 1: Product Approval - The new veterinary drug is a trivalent inactivated vaccine for feline panleukopenia, feline calicivirus, and feline infectious respiratory disease [1] - The vaccine was jointly submitted by the company and its wholly-owned subsidiaries, Luoyang Huizhong Biotechnology Co., Ltd. and Luoyang Huizhong Animal Health Co., Ltd. [1] - The new veterinary drug registration certificate was officially issued on September 29, 2025, as per the announcement by the Ministry of Agriculture and Rural Affairs [1] Group 2: Vaccine Efficacy - The vaccine is designed to prevent feline panleukopenia, feline calicivirus disease, and feline infectious respiratory disease [1] - The immune response is expected to develop within 7 days after the second vaccination, with an immunity duration of 12 months [1]

Core Viewpoint - The company, Pulike (603566.SH), has received approval from the Ministry of Agriculture and Rural Affairs for a new veterinary drug, specifically a trivalent inactivated vaccine for cats, which targets feline panleukopenia, calicivirus, and rhinotracheitis [1] Group 1 - The new veterinary drug is a joint application by Pulike and its wholly-owned subsidiaries, Luoyang Huizhong Biotechnology Co., Ltd. and Luoyang Huizhong Animal Health Co., Ltd. [1] - The approval includes the issuance of the New Veterinary Drug Registration Certificate, as announced in the Ministry of Agriculture and Rural Affairs' public notice No. 953 [1] - The vaccine is expected to be publicly available by September 29, 2025 [1]